There may also be mileage in a composite biomarker approach given that, for example, in gastric cancer the combination of EBV and PD-L1-positivity but not MSI-H status was associated with response to checkpoint inhibition [64, 65]. This evidence concerns the gene CD274 and gastric cancer.